Market Intelligence, Isoform-Selective Therapeutics, and High-Fidelity Kinase Reagents for Cardiac & Neurological Indications.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CAMK2B drug discovery.
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (Active Kinase) | CAMK2B Full-Length Recombinant Protein (T287D Constitutively Active Mutant) High purity (>95%), Sequence Verified, Auto-phosphorylation sites preserved. Theoretical MW ~60 kDa. |
View CAMK2B Products |
| Antigen (Kinase-Dead Control) | CAMK2B K43R Mutant (ATP-binding defective) For negative control in activity assays. High purity (>95%). |
View CAMK2B Products |
| Antigen (WT) | CAMK2B Full-Length Active Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View CAMK2B Products |
| Gene Delivery | CAMK2B Promise-ORF Lentivirus (WT, T287D, K43R) For stable neuronal and cardiomyocyte cell line construction. |
View CAMK2B Products |
| Isoform Panel | CAMK2A, CAMK2D, CAMK2G Recombinant Proteins For isoform selectivity screening. |
View CAMK2A Products |
| Co-Factor | CALM1 (Calmodulin-1) Recombinant Protein Ca²⁺-binding partner required for CAMK2B activation assays. |
View CALM1 Products |
| Benchmark Ab | Anti-CAMK2B (Phospho-Thr287 Specific) Monoclonal Antibody Recombinant rabbit mAb, sequence verified. |
View CAMK2B Products |
| Validator | CAMK2B siRNA Set (3 unique sequences) For knockdown verification and specificity controls. |
View CAMK2B Products |
| Related Target A | CAMK2A (CaMKIIα) Neuronal isoform for selectivity counter-screening. |
View CAMK2A Products |
| Related Target B | CAMK2D (CaMKIIδ) Cardiac isoform for off-target profiling. |
View CAMK2D Products |
| Related Target C | RYR2 (Ryanodine Receptor 2) Downstream substrate in cardiac excitation-contraction coupling. |
View RYR2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Isoform Selectivity (CAMK2B vs CAMK2D vs CAMK2A) | Human/Mouse/Rat ortholog panel of all four CAMK2 isoforms (A/B/D/G), >95% purity, sequence-verified by mass spec for identical ATP-binding pocket contexts. |
| Auto-phosphorylation State Control | Available in Unphosphorylated (basal) and T287D (Constitutively Active) forms; Endotoxin <1EU/µg for cellular assays. |
| Holoenzyme Assembly Validation | Full-length proteins retaining hub domains (residues 1-478) for dodecamer oligomerization studies via SEC-MALS. |
| Ca²⁺/CaM Dependent Activation Kinetics | Matched CALM1 co-factor available; HEK293 expressed ensuring mammalian glycosylation patterns on regulatory domain. |
| Cellular Target Engagement | Lentivirus particles for stable expression in iPSC-derived cardiomyocytes and neurons; Puromycin selectable. |
| Cross-species Evaluation | Human/Mouse/Cyno CAMK2B ortholog proteins available with >95% purity. Sequence Verified. |
Live CAMK2B R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic landscape for CaMKII (CAMK2) inhibitors is undergoing a strategic pivot. Historically limited by the highly conserved ATP-binding pocket across the CAMK family, the field is shifting toward isoform-selective and non-ATP competitive mechanisms targeting the hub domain, CaM-binding regulatory region, or allosteric sites. CAMK2B, the predominant neuronal isoform, is gaining traction for neurodevelopmental disorders (e.g., Angelman Syndrome), metastatic cancer (EMT induction), and cognitive deficits. Cardiac programs increasingly differentiate between CAMK2D (cardiac-dominant) and CAMK2B to avoid CNS side effects. First-generation pan-CaMKII small molecules face toxicity due to cross-isoform activity; the next wave emphasizes allosteric modulators, PROTACs, and gene-silencing (ASO/siRNA). Key applications span heart failure, arrhythmia, epilepsy, and rare neurological conditions. The emergence of hub-domain inhibitors and substrate-selective inhibition strategies promises improved therapeutic windows.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (ATP-competitive) | Merck, Academic Consortia | Heart Failure, Arrhythmia, Epilepsy | Kinase Activity Assay (Need active T287D mutant vs WT); Isoform selectivity panel (A/B/D/G) |
| Small Molecule (Allosteric/Hub Domain) | University Labs (Bers, Schulman), Early-stage Biotechs | Cardiac Remodeling, Neurological Disease | Oligomerization Disruption Assay (SEC-MALS); Need full-length hub-intact proteins |
| Peptide Inhibitor (CaM-binding domain) | Start-ups (e.g., CaMKinase Therapeutics) | Angelman Syndrome, Autism, Cardiac Protection | CaM-Competition Binding Assay (SPR/BLI); Cell Permeability via Lentivirus-expressed reporters |
| PROTAC / Degrader | Emerging Biotechs, Preclinical Pharms | Neurodegenerative Diseases, Oncology | Ternary Complex Formation (Need strictly Sequence-Verified proteins + E3 ligase components) |
| Gene Therapy (ASO/siRNA/AAV) | Major Pharma (Biogen), Spark | Rare Neurodevelopmental Disorders, Congenital Heart Disease | siRNA Validation Tools; Isoform-specific antibody detection; Cell Line Engineering (Lentivirus) |
Key Mutations and Functional Domains
CAMK2B contains a canonical Protein kinase domain (UniProt Q13554). Disease-relevant mutations include three variants linked to MRD54 (Mental Retardation, Autosomal Dominant 54):
- VAR_080588: A point mutation associated with MRD54.
- VAR_080589 and VAR_080590: Both lead to decreased protein abundance, increased autophosphorylation, and decreased kinase activity (specific functional outcomes vary). These mutants serve as critical tools for studying isoform-specific pathology and developing mutation-selective therapeutics. TarMart provides corresponding mutant proteins (e.g., T287D, K43R) and validated siRNA for mechanistic validation.
About This Report
This integrated analysis consolidates market intelligence from multiple sources, emphasizing CAMK2B biology, competitive landscape, and high-purity reagent solutions. All product references link to the TarMart catalog. For detailed assay design, consult our technical team.